Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

BlackRock Capital Investment Corporation Reports Financial Results for the Quarter Ended March 31, 2019, Declares Quarterly Distribution of $0.18 per Share

Published

on

Reading Time: 13 minutes

  • GAAP Net Investment Income (NII) of $0.17 per share providing first
    quarter distribution coverage of approximately 92%.
  • Net Asset Value (NAV) per share increased 1.1% or $0.08 per share to
    $7.15 per share on a quarter-over-quarter basis.
  • Net leverage of 0.37x was slightly up reflecting a net increase in
    investments. Total liquidity for portfolio company investments,
    including cash, was approximately $268.8 million, subject to leverage
    and borrowing base restrictions.
  • Under our existing share repurchase program, we repurchased 85,543
    shares of common stock for $0.5 million at an average price of $5.49,
    including brokerage commissions, via open market purchases in the
    first quarter.

NEW YORK–(BUSINESS WIRE)–BlackRock Capital Investment Corporation (NASDAQ:BKCC) (“BCIC” or the
“Company,” “we,” “us” or “our”) announced today that its Board of
Directors declared a quarterly distribution of $0.18 per share, payable
on July 9, 2019 to stockholders of record at the close of business on
June 18, 2019.

“Our deployment pipeline remains robust heading into the second quarter,
reflecting the increased capabilities of our platform following the
integration of Tennenbaum Capital Partners LLC, or TCP, with the
Company’s adviser, BlackRock Capital Investment Advisors, LLC. Two of
the new investments made by the Company during the quarter were driven
by BlackRock-managed funds being able to provide a holistic financing
solution to our borrowers. For the second quarter, we anticipate
investments in new companies to trend higher based on our current
pipeline and completed investments thus far in the second quarter.
Additionally, we believe that our ability to co-invest with TCP
affiliated funds allows us to mitigate portfolio risk by increasing
issuer and sector diversity,” commented James E. Keenan, Chairman and
Interim CEO of the Company.

“Our net unrealized and realized gains of $6.6 million were a result of
net portfolio valuation increases, primarily driven by appreciation in
our equity investment in US Well Services, Inc. (“USWS”). We anticipate
that the valuation of our USWS investment will continue to shift in line
with the quarter-end closing prices of the USWS stock. Substantially all
of our investment in USWS is subject to lock-ups, half of which expire
in May 2019 and the other half in November 2019.

“Under BlackRock’s management of BCIC, from March 6, 2015 to March 31,
2019, we have deployed capital of approximately $1 billion, of which
$387 million has been exited with a realized IRR of 14.1%. With
liquidity at approximately $269 million and no debt maturities until
2022, we have significant operating flexibility and deployment capacity.”

Financial Highlights

     
Q1 2019 Q4 2018 Q1 2018
($’s in millions, except per share data)      

Total
Amount

    Per Share    

Total
Amount

    Per Share    

Total
Amount

    Per Share
               
Net Investment Income/(loss) $ 11.4 $ 0.17 $ 11.8 $ 0.17 $ 11.6 $ 0.16
Net realized and unrealized gains/(losses) $ 6.6 $ 0.09 $ (46.4 ) $ (0.66 ) $ (12.5 ) $ (0.17 )
Deferred taxes $ 2.2 $ 0.03
Basic earnings/(losses) $ 18.0 $ 0.26 $ (32.4 ) $ (0.46 ) $ (0.9 ) $ (0.01 )
Distributions declared $ 12.4 $ 0.18 $ 12.6 $ 0.18 $ 13.2 $ 0.18
Net Investment Income/(loss), as adjusted1 $ 11.4 $ 0.17 $ 11.8 $ 0.17 $ 11.6 $ 0.16
Basic earnings/(losses), as adjusted1       $ 18.0     $ 0.26     $ (32.4 )     $ (0.46 )     $ (0.9 )     $ (0.01 )
($’s in millions, except per share data)       March 31,

2019

  December 31,

2018

  March 31,

2018

         
Total assets $721.8 $693.6 $887.1
Investment portfolio, at fair market value $680.4 $671.7 $870.1
Debt outstanding $208.8 $186.4 $310.1
Total net assets $492.1 $487.0 $553.1
Net asset value per share $7.15 $7.07 $7.65
Net leverage ratio2       0.37x     0.36x     0.56x

Business Updates

  • Under our existing share repurchase program, during the first quarter
    of 2019, 85,543 shares were repurchased for $0.5 million at an average
    price of $5.49 per share, including brokerage commissions. The
    cumulative repurchases since BlackRock entered into the investment
    management agreement with the Company in early 2015 totaled
    approximately 7.3 million shares for $50.4 million, representing 80.4%
    of total share repurchase activity, on a dollar basis, since
    inception. Since the inception of our share repurchase program through
    March 31, 2019, we have purchased 9.0 million shares at an average
    price of $6.94 per share, including brokerage commissions, for a total
    of $62.7 million. As of March 31, 2019, 3,320,309 shares remained
    authorized for repurchase.
  • The non-core legacy asset book comprised 33% of our total portfolio by
    fair market value as of March 31, 2019. This is further broken down
    into income-producing investments, non-earning equities and
    non-accrual investments at 25%, 7% and 1% of the total portfolio,
    respectively, by fair market value. Our investments in Vertellus
    Holdings, AGY Holding, Sur La Table, US Well Services and related
    issuers comprise 73% of the non-core book by fair market value.
___________________________
1 Non-GAAP basis financial measure. See Supplemental
Information on page 8.
2 Calculated as the ratio between (A) debt, excluding
unamortized debt issuance costs, less available cash and receivable
for investments sold, and (B) net asset value.
 

Portfolio and Investment Activity*

($’s in millions)      

Three Months
ended
March 31, 2019

 

   

Three Months
ended
December 31, 2018

 

   

Three Months
ended
March 31, 2018

 

             
Investment deployments $ 58.0 $ 32.0 $ 144.6
Investment exits $ 55.7 $ 94.7 $ 17.2
Number of portfolio company investments at the end of period 28 27 31
Weighted average yield of debt and income producing equity
securities,

at fair market value

11.7 % 11.5 % 11.3 %
% of Portfolio invested in Secured debt, at fair market value 47 % 47 % 59 %
% of Portfolio invested in Unsecured debt, at fair market value 23 % 23 % 16 %
% of Portfolio invested in Equity, at fair market value 30 % 30 % 25 %
Average investment by portfolio company, at amortized cost

(excluding investments below $5.0 million)

      $ 32.5       $ 34.1       $ 33.6  
 

*Balance sheet amounts above are as of period end

  • We deployed $58.0 million during the quarter while exits of
    investments totaled $55.7 million, resulting in a $2.3 million net
    increase in our portfolio due to investment activity.

    • Our deployments were primarily concentrated in three new portfolio
      company investments and one investment into an existing portfolio
      company.

      • $7.5 million funded L + 6.75% first lien term loan (with an
        additional $2.5 million unfunded at close) to
        FinancialForce.com, a provider of cloud ERP and Professional
        Service Automation (“PSA”) software;
      • $4.7 million funded L + 7.25% first lien term loan (with a
        $0.4 million unfunded revolver) to CareATC, Inc., a
        tech-enabled provider of employer-sponsored health and
        wellness clinics;
      • $21.0 million funded L + 8.50% second lien term loan to
        Paragon Films, a leading manufacturer or stretch films
        servicing the storage and distribution pallet unitization
        market; and
      • $23.9 million of incremental L + 11.0% unsecured debt to
        Gordon Brothers Finance Company (“GBFC”) to fund portfolio
        growth.
    • Our repayments were primarily concentrated in one portfolio
      company exit and two partial repayments:

      • $25.0 million repayment of Paragon Films second lien term
        loan. The exit of this investment occurred pursuant to a sale
        of the company to a new sponsor and accompanying
        recapitalization. The aforementioned $21.0 million investment
        in Paragon Films was an investment in the post-sale capital
        structure;
      • $26.1 million partial repayment of unsecured debt to GBFC;
      • $3.0 million partial repayment of NorthStar Financial second
        lien term loan; and
    • A $3.0 million revolver commitment to Bankruptcy Management
      Solutions was terminated resulting in a complete exit from this
      investment. The revolver was unfunded.
  • Our $96.3 million equity investment in BCIC Senior Loan Partners
    (“SLP”) is generating a yield of greater than 12%. During the first
    quarter, SLP made investments into one new portfolio company and four
    existing portfolio companies totaling $11.9 million of new capital
    deployments during the quarter. Total committed capital and
    outstanding investments, at par, amounted to $369.7 million and $354.5
    million, respectively, to 28 borrowers. The new investment, at par,
    was a $3.1 million first lien term loan to Research Now Group, LLC, a
    global leader in data collection through online, mobile, and offline
    surveys. Incremental investments to existing portfolio companies
    primarily included an additional $4.1 million investment in Protective
    Industrial Products, Inc., and an additional $3.6 million investment
    in MSHC, Inc. (Service Logic Acquisition).
  • As of March 31, 2019, there were three non-accrual investment
    positions, representing approximately 1.6% and 7.0% of total debt and
    preferred stock investments, at fair value and cost, respectively, as
    compared to non-accrual investment positions of approximately 1.6% and
    7.1% of total debt and preferred stock investments at fair value and
    cost, respectively, at December 31, 2018. Our average internal
    investment rating at fair market value at March 31, 2019 was 1.49 as
    compared to 1.44 as of the prior quarter end.
  • During the quarter ended March 31, 2019, net realized and unrealized
    gains were $6.6 million, primarily due to appreciation in portfolio
    valuations during the quarter.

First Quarter Financial Updates

  • GAAP net investment income (“NII”) was $11.4 million, or $0.17 per
    share, for the three months ended March 31, 2019. Relative to
    distributions declared of $0.18 per share, our NII distribution
    coverage was 92% for the quarter.
  • As previously disclosed, our base management fee rate was reduced from
    an annual rate of 2.00% of total assets to 1.75%, effective March 7,
    2017, and incentive management fees based on income were waived by our
    investment adviser until June 30, 2019. For the quarter ended March
    31, 2019, we incurred base management fees of $2.9 million. Incentive
    management fees based on income of $2.3 million were earned and waived
    by our adviser during the current quarter. Additionally, $18.8 million
    of incentive management fees have been waived on a cumulative basis.
    For incentive management fees based on gains, there was no accrual as
    of March 31, 2019.
  • Tax characteristics of all 2018 distributions were reported to
    stockholders on Form 1099 after the end of the calendar year. Our 2018
    distributions of $0.72 per share were comprised of $0.70 per share
    from various sources of income and $0.02 per share of return of
    capital. Our return of capital distributions totaled $1.98 per share
    from inception to December 31, 2018. At our discretion, we may carry
    forward taxable income in excess of calendar year distributions and
    pay a 4% excise tax on this income. We will accrue excise tax on
    estimated undistributed taxable income as required. There was no
    undistributed taxable income carried forward from 2018.

Liquidity and Capital Resources

  • At March 31, 2019, we had $27.1 million in cash and cash equivalents
    and $241.7 million of availability under our credit facility, subject
    to leverage restrictions, resulting in approximately $268.8 million of
    availability for portfolio company investments.
  • Net leverage, adjusted for available cash, receivables for investments
    sold, payables for investments purchased and unamortized debt issuance
    costs, stood at 0.37x at quarter-end, and our 328% asset coverage
    ratio provided the Company with available debt capacity under its
    asset coverage requirements of $274.7 million. Further, as of
    quarter-end, approximately 77% of our portfolio was invested in
    qualifying assets, exceeding the 70% regulatory requirement of a
    business development company.

Conference Call

BlackRock Capital Investment Corporation will host a
webcast/teleconference at 10:00 a.m. (Eastern Time) on Thursday, May 2,
2019, to discuss its first quarter 2019 financial results. All
interested parties are welcome to participate. You can access the
teleconference by dialing, from the United States, (800) 458-4148, or
from outside the United States, +1-720-543-0206, 10 minutes before 10:00
a.m. and referencing the BlackRock Capital Investment Corporation
Conference Call (ID Number 3027722). A live, listen-only webcast will
also be available via the Investor Relations section of www.blackrockbkcc.com.
Both the teleconference and webcast will be available for replay by 1:00
p.m. on Thursday, May 2, 2019 and ending at 1:00 p.m. on Thursday, May
16, 2019. To access the replay of the teleconference, callers from the
United States should dial (888) 203-1112 and callers from outside the
United States should dial (719) 457-0820 and enter the Conference ID
Number 3027722.

Prior to the webcast/teleconference, an investor presentation that
complements the earnings conference call will be posted to BlackRock
Capital Investment Corporation’s website within the Presentations
section of the Investors page (http://www.blackrockbkcc.com/news-and-events/disclaimer).

About BlackRock Capital Investment Corporation

BlackRock Capital Investment Corporation is a business development
company that provides debt and equity capital to middle-market companies.

The Company’s investment objective is to generate both current income
and capital appreciation through debt and equity investments. The
Company invests primarily in middle-market companies in the form of
senior and junior secured and unsecured debt securities and loans, each
of which may include an equity component, and by making direct
preferred, common and other equity investments in such companies.

         

BlackRock Capital Investment Corporation

Consolidated Statements of Assets and Liabilities

 
        March 31,

2019

    December 31,

2018

Assets
Investments at fair value:
Non-controlled, non-affiliated investments (cost of $253,938,127 and
$233,331,450)
$ 218,148,636 $ 200,569,644
Non-controlled, affiliated investments (cost of $114,252,403 and
$130,892,674)
99,991,510 111,727,234
Controlled investments (cost of $387,251,367 and $388,870,375)   362,234,127     359,356,068  
Total investments at fair value (cost of $755,441,897 and
$753,094,499)
680,374,273 671,652,946
Cash and cash equivalents 27,107,015 13,497,320
Receivable for investments sold 2,002,968 1,691,077
Interest, dividends and fees receivable 9,945,510 4,084,001
Prepaid expenses and other assets   2,368,966     2,707,036  
Total Assets $ 721,798,732   $ 693,632,380  
Liabilities
Debt (net of deferred financing costs of $2,997,396 and $3,227,965) $ 208,835,348 $ 186,397,728
Interest and credit facility fees payable 2,576,255 722,841
Distributions payable 12,390,525 12,552,212
Base management fees payable 2,923,149 3,494,520
Payable for investments purchased 989,460
Accrued administrative services 739,812 376,507
Other accrued expenses and payables   2,204,539     2,078,958  
Total Liabilities   229,669,628     206,612,226  
Net Assets
Common stock, par value $.001 per share, 200,000,000 common shares
authorized,
77,861,287 and 77,861,287 issued and 68,836,255 and 68,921,798
outstanding
77,861 77,861
Paid-in capital in excess of par 853,248,794 853,248,794
Distributable earnings (losses) (298,528,296 ) (304,106,473 )
Treasury stock at cost, 9,025,032 and 8,939,489 shares held   (62,669,255 )   (62,200,028 )
Total Net Assets   492,129,104     487,020,154  
Total Liabilities and Net Assets $ 721,798,732   $ 693,632,380  
Net Asset Value Per Share       $ 7.15       $ 7.07  
 

BlackRock Capital Investment Corporation

Consolidated Statements of Operations

         
       

Three Months
ended
March 31, 2019
(Unaudited)

   

Three Months
ended
March 31, 2018
(Unaudited)

Investment Income:
Non-controlled, non-affiliated investments:
Cash interest income $ 5,942,016 $ 7,144,027
PIK interest income 240,184
Fee income   475,407     465,206  
Total investment income from non-controlled, non-affiliated
investments
  6,657,607     7,609,233  
Non-controlled, affiliated investments:
Cash interest income 1,222,251 2,214,613
PIK interest income 690,960
PIK dividend income 220,480 189,026
Fee income       35,000  
Total investment income from non-controlled, affiliated investments   1,442,731     3,129,599  
Controlled investments:
Cash interest income 6,900,738 5,085,705
PIK interest income 766,466
Cash dividend income 4,191,703 3,126,861
PIK dividend income 731,516
Fee income   121,862     387,058  
Total investment income from controlled investments   11,214,303     10,097,606  
Total investment income   19,314,641     20,836,438  
Expenses:
Base management fees 2,923,149 3,312,369
Incentive management fees 2,280,836 1,735,195
Interest and credit facility fees 3,392,434 3,708,958
Professional fees 473,043 733,164
Administrative services 363,305 553,764
Director fees 193,000 187,000
Investment advisor expenses 87,500 87,500
Other   478,029     630,737  
Total expenses, before incentive management fee waiver   10,191,296     10,948,687  
Incentive management fee waiver   (2,280,836 )   (1,735,195 )
Expenses, net of incentive management fee waiver   7,910,460     9,213,492  
Net Investment Income   11,404,181     11,622,946  
 
Realized and Unrealized Gain (Loss):
Net realized gain (loss):
Non-controlled, non-affiliated investments 325,489 (50,515,956 )
Non-controlled, affiliated investments (269,226 )
Controlled investments       (26,118,432 )
Net realized gain (loss)   56,263     (76,634,388 )
Net change in unrealized appreciation (depreciation) on:
Non-controlled, non-affiliated investments (2,684,053 ) 43,690,517
Non-controlled, affiliated investments 4,560,914 1,422,575
Controlled investments 4,497,067 19,156,544
Foreign currency translation   134,330     (173,911 )
Net change in unrealized appreciation (depreciation)   6,508,258     64,095,725  
Net realized and unrealized gain (loss)   6,564,521     (12,538,663 )
Net Increase (Decrease) in Net Assets Resulting from Operations $ 17,968,702   $ (915,717 )
Net Investment Income Per Share-basic $ 0.17   $ 0.16  
Earnings (Loss) Per Share-basic $ 0.26   $ (0.01 )
Average Shares Outstanding-basic   68,837,612     72,991,828  
Net Investment Income Per Share-diluted $ 0.16   $ 0.15  
Earnings (Loss) Per Share-diluted $ 0.24   $ (0.01 )
Average Shares Outstanding-diluted   85,831,349     89,985,565  
Distributions Declared Per Share       $ 0.18       $ 0.18  
 

Supplemental Information

The Company reports its financial results on a GAAP basis; however,
management believes that evaluating the Company’s ongoing operating
results may be enhanced if investors have additional non-GAAP basis
financial measures. Management reviews non-GAAP financial measures to
assess ongoing operations and, for the reasons described below,
considers them to be effective indicators, for both management and
investors, of the Company’s financial performance over time. The
Company’s management does not advocate that investors consider such
non-GAAP financial measures in isolation from, or as a substitute for,
financial information prepared in accordance with GAAP.

Until March 6, 2017, the Company recorded its liability for incentive
management fees based on income as it became legally obligated to pay
them, based on a hypothetical liquidation at the end of each reporting
period. The Company’s obligation to pay incentive management fees with
respect to any fiscal quarter until March 6, 2017 was based on a formula
that reflects the Company’s results over a trailing four-fiscal quarter
period ending with the pro-rated period until March 6, 2017. The Company
is legally obligated to pay the amount resulting from the formula less
any cash payments of incentive management fees during the prior three
quarters. The formula’s requirement to reduce the incentive management
fee by amounts paid with respect to such fees in the prior three
quarters caused the Company’s incentive management fee expense to become
concentrated in the fourth quarter of each year. Management believes
that reflecting incentive management fees throughout the year, as the
related investment income is earned, is an effective measure of the
Company’s profitability and financial performance that facilitates
comparison of current results with historical results and with those of
the Company’s peers. The Company’s “as adjusted” results reflect
incentive management fees based on the formula the Company utilizes for
each trailing four-fiscal quarter period until March 6, 2017, with the
formula applied to each quarter’s incremental earnings and without any
reduction for incentive management fees paid during the prior three
quarters. The resulting amount represents an upper limit of each
quarter’s incremental incentive management fees that the Company may
become legally obligated to pay at the end of the year. Prior year
amounts are estimated in the same manner. These estimates represent
upper limits because, in any calendar year, subsequent quarters’
investment underperformance could reduce the incentive management fees
payable by the Company with respect to prior quarters’ operating
results. After March 6, 2017, incentive management fees based on income
have been calculated for each calendar quarter and are paid on a
quarterly basis if certain thresholds are met. The Company records its
liability for incentive management fees based on capital gains by
performing a hypothetical liquidation at the end of each reporting
period. The accrual of this hypothetical capital gains incentive
management fee is required by GAAP, but it should be noted that a fee so
calculated and accrued is not due and payable until the end of the
measurement period, or every June 30. The incremental incentive
management fees disclosed for a given period are not necessarily
indicative of actual full year results. Changes in the economic
environment, financial markets and other parameters used in determining
such estimates could cause actual results to differ and such differences
could be material. In addition, on March 7, 2017, BlackRock Advisors, in
consultation with the Company’s Board of Directors, agreed to waive
incentive fees based on income after March 6, 2017 to December 31, 2018,
which was extended to June 30, 2019. BCIA has agreed to honor such
waiver. For a more detailed description of the Company’s incentive
management fee, please refer to the Company’s Annual Report on Form 10-K
for the fiscal year ended December 31, 2018, on file with the Securities
and Exchange Commission (“SEC”).

Computations for the periods below are derived from the Company’s
financial statements as follows:

         
       

Three months
ended
March 31, 2019

 

   

Three months
ended
March 31, 2018

 

GAAP Basis:
Net Investment Income $ 11,404,181 $ 11,622,946
Net Investment Income per share 0.17 0.16
Addback: GAAP incentive management fee expense based on Gains
Addback: GAAP incentive management fee expense based on Income
Pre-Incentive Fee 1 :
Net Investment Income $ 11,404,181 $ 11,622,946
Net Investment Income per share 0.17 0.16
Less: Incremental incentive management fee expense based on Income
As Adjusted 2 :
Net Investment Income $ 11,404,181 $ 11,622,946
Net Investment Income per share         0.17       0.16
 
Note: The Net Investment Income amounts for the three months ended
March 31, 2019 and 2018 are net of incentive management fees based
on income and a corresponding incentive management fee waiver in the
amounts of $2,280,836 and $1,735,195, respectively. For the periods
shown, there is no difference between the GAAP and as adjusted
figures; however, there may be a difference in future periods.
 

1 Pre-Incentive Fee: Amounts are adjusted to
remove all incentive management fees. Such fees are calculated but
not necessarily due and payable at this time.

 

2 As Adjusted: Amounts are adjusted to remove
the incentive management fee expense based on gains, as required
by GAAP, and to include only the incremental incentive management
fee expense based on Income. Until March 6, 2017, the incremental
incentive management fee was calculated based on the current
quarter’s incremental earnings, and without any reduction for
incentive management fees paid during the prior calendar quarters.
After March 6, 2017, incentive management fee expense based on
income has been calculated for each calendar quarter and may be
paid on a quarterly basis if certain thresholds are met. Amounts
reflect the Company’s ongoing operating results and reflect the
Company’s financial performance over time.

 

Contacts

Investor Contact:
Nik Singhal
212.810.5427

Press
Contact:

Brian Beades
212.810.5596

Read full story here


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Cannabis

Medical Cannabis Market Report 2024-2030: Asia-Pacific Set to Witness Robust Growth, Driven by R&D Discovery Initiatives

Published

on

Continue Reading

Cannabis

Rubicon Organics Reports Q1 2024 Financial Results

Published

on

Continue Reading

SCHWAZZE

Schwazze Announces First Quarter 2024 Financial Results

Published

on

schwazze-announces-first-quarter-2024-financial-results

Schwazze Management to Host Conference Call Today at 5:00 p.m. Eastern Time

DENVER, May 15, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (Cboe CA: SHWZ) (“Schwazze” or the “Company”), today announced financial and operational results for the first quarter ended March 31, 2024.

“We delivered another period of revenue growth in Q1 as we further refined our retail strategy while contending with the prolonged competitive challenges in Colorado and New Mexico,” said Forrest Hoffmaster, Interim CEO of Schwazze. “Throughout the quarter, we continued to sharpen our pricing and promotional efforts while enhancing the in-store experience, widening assortment, improving in-stock position, and advancing our loyalty program to attract and retain new customers. We also strengthened our wholesale business with quarter-over-quarter growth, while surpassing 30% total door penetration across both states.”

“The Colorado market remains highly competitive with more than 680 active recreational licenses, underscoring the importance of delivering an exceptional customer experience and fully integrated retail support program. Although retail pricing has recently stabilized, Colorado sales in Q1 were down 10% year-over-year due to lower volumes. Nonetheless, we significantly outpaced the market as our sales were up 9%, demonstrating the effectiveness of our operating playbook to compete in challenging environments. We expect to continue driving improvements in customer acquisition, retention, and loyalty as we further increase market share in the state.”

“In New Mexico, the proliferation of new licenses continued to outpace state cannabis sales as store count in Q1 increased 31% year-over-year while the market grew only 13%. In addition to pricing and promotional efforts, we’ve focused on driving traffic into our stores by expanding assortment with high quality flower and delivering an elevated customer experience. The New Mexico regulatory body has also increased its license enforcement efforts in recent months, contributing to more than 70 store closures and a 33% sequential decrease in net new store openings in the first quarter. We will continue to support the New Mexico Cannabis Control Division as it develops its regulatory framework.”

“Over the past four years we have rapidly scaled our footprint through 13 acquisitions, building a leading retail presence in both Colorado and New Mexico. We are beginning to see positive momentum from our pricing and promotional strategy and will remain focused on driving operating efficiencies while further optimizing our assets as we consolidate cultivation facilities and eliminate underperforming stores that do not meet our high-margin thresholds. We believe these initiatives, coupled with our operating playbook and strict cost controls, will enable us to return to stronger levels of profitability moving forward.”

First Quarter 2024 Financial Summary

$ in Thousands USD

Q1 2024

Q4 2023

Q1 2023

Total Revenue

$41,601

$43,325

$40,001

Gross Profit

$17,934

$7,034[1]

$21,849

Operating Expenses

$20,643

$23,276

$16,199

Income (Loss) from Operations

$(2,709)

$(16,242)

$5,650

Adjusted EBITDA[2]

$7,341

$10,953

$14,525

Operating Cash Flow

$(3,700)

$3,452

$(880)

Recent Highlights

  • Announced the grand opening of a medical and recreational dispensary in March under the Everest Apothecary banner in Las Cruces, New Mexico, increasing the Company’s retail footprint to 34 stores across the state.
  • Increased wholesale penetration in the first quarter to more than 30% of total doors in Colorado and New Mexico.
  • Lowell Herb Co. pre-roll sales increased more than 3x quarter-over-quarter in Colorado, where it continues to be the #1 pre-roll in the state.
  • Wana gummy sales up more than 2x quarter-over-quarter in New Mexico.

First Quarter 2024 Financial Results

Total revenue in the first quarter of 2024 increased 4% to $41.6 million compared to $40.0 million for the same quarter last year. The increase was primarily due to growth from new stores compared to the prior year period, partially offset by continued pricing pressure and the proliferation of new licenses in New Mexico.

Gross profit for the first quarter of 2024 was $17.9 million or 43.1% of total revenue, compared to $21.8 million or 54.6% of total revenue for the same quarter last year. The decrease in gross margin was primarily driven by the aforementioned pricing pressure in New Mexico, as well as higher medical sales mix in Colorado.

____________________________

1 Q4 2023 Gross Profit includes one-time, non-cash inventory adjustments of approximately $13.1 million comprised of $3.1 million of product consolidation, obsolescence, and shrinkage expenses, $4.3 million of net realizable value adjustments, and $5.8 million of fair value adjustments on acquired inventory in New Mexico in 2023. 
2  Adjusted EBITDA is a non-GAAP measure as defined by the SEC, and represents earnings before interest, taxes, depreciation, and amortization, adjusted for other income, non-cash share-based compensation, one-time transaction related expenses, or other non-operating costs. The Company uses Adjusted EBITDA as it believes it better explains the results of its core business. See “ADJUSTED EBITDA RECONCILIATION (NON-GAAP)” section herein for an explanation and reconciliations of non-GAAP measure used throughout this release.

Operating expenses for the first quarter of 2024 were $20.6 million compared to $16.2 million for the same quarter last year. The year-ago period benefitted from a payroll tax credit of $3.9M. The remaining increase was primarily driven by personnel expenses and four-wall SG&A costs associated with 21 additional stores in Colorado and New Mexico that are still ramping.

Loss from operations for the first quarter of 2024 was $2.7 million compared to income from operations of $5.6 million in the same quarter last year. Net loss was $16.1 million for the first quarter of 2024 compared to net income of $1.7 million for the same quarter last year.

Adjusted EBITDA for the first quarter of 2024 was $7.3 million compared to $14.5 million for the same quarter last year. The decrease in Adjusted EBITDA was primarily driven by lower gross margin and higher operating expenses associated with the 21 additional stores that are still ramping.

As of March 31, 2024, cash and cash equivalents were $13.2 million compared to $19.2 million on December 31, 2023. Total debt as of March 31, 2024, was $159.7 million compared to $156.8 million on December 31, 2023.

Conference Call

The Company will conduct a conference call today, May 15, 2024, at 5:00 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2024.

Schwazze management will host the conference call, followed by a question-and-answer period. Interested parties may submit questions to the Company prior to the call by emailing [email protected].

Date: Wednesday, May 15, 2024
Time: 5:00 p.m. Eastern time
Toll-free dial-in: (888) 664-6383
International dial-in: (416) 764-8650
Conference ID: 84167910
Webcast: SHWZ Q1 2024 Earnings Call

The conference call will also be broadcast live and available for replay on the investor relations section of the Company’s website at https://ir.schwazze.com.

Toll-free replay number: (888) 390-0541
International replay number: (416) 764-8677
Replay ID: 167910

If you have any difficulty registering or connecting with the conference call, please contact Elevate IR at (720) 330-2829.

About Schwazze

Schwazze (OTCQX: SHWZ) (Cboe CA: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to explore taking its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include financial outlooks; any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of our management team for future operations; expectations in connection with the Company’s previously announced business plans; any statements regarding future economic conditions or performance; and statements regarding the intent, belief or current expectations of our management team. Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. We have based our forward-looking statements on management’s current expectations and assumptions about future events and trends affecting our business and industry. Although we do not make forward-looking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Therefore, forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected]

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
For the Periods Ended March 31, 2024 and December 31, 2023
Expressed in U.S. Dollars

 March 31,

December 31, 

2024

2023

 

ASSETS

 

Current Assets

Cash & Cash Equivalents

$

13,151,317

$

19,248,932

Accounts Receivable, net of Allowance for Doubtful Accounts

3,356,032

4,261,159

Inventory

26,382,184

25,787,793

Marketable Securities, net of Unrealized Loss of $347,516 and Loss of $1,816, respectively

108,583

456,099

Prepaid Expenses & Other Current Assets

3,502,310

3,914,064

Total Current Assets

46,500,426

53,668,047

Non-Current Assets

Fixed Assets, net Accumulated Depreciation of $10,061,700 and $8,741,782, respectively

31,326,000

31,113,630

Investments

2,000,000

2,000,000

Investments Held for Sale

202,111

Goodwill

67,492,705

67,499,199

Intangible Assets, net Accumulated Amortization of $36,483,160 and $32,706,765, respectively

162,391,482

166,167,877

Other Non-Current Assets

1,328,187

1,263,837

Operating Lease Right of Use Assets

34,575,832

34,233,142

Deferred Tax Assets, net

992,144

1,996,489

Total Non-Current Assets

300,106,350

304,476,285

Total Assets

$

346,606,776

$

358,144,332

 

LIABILITIES & STOCKHOLDERS’ EQUITY

 

Current Liabilities

Accounts Payable

$

9,443,233

$

13,341,561

Accrued Expenses

8,106,618

7,774,691

Derivative Liabilities

1,319,845

638,020

Lease Liabilities – Current

5,186,316

4,922,724

Current Portion of Long Term Debt

29,579,713

3,547,011

Income Taxes Payable

28,235,039

25,232,782

Total Current Liabilities

81,870,764

55,456,789

Non-Current Liabilities

Long Term Debt, net of Debt Discount & Issuance Costs

130,120,753

153,262,203

Lease Liabilities – Non-Current

30,735,072

30,133,452

Total Non-Current Liabilities

160,855,825

183,395,655

Total Liabilities

$

242,726,589

$

238,852,444

Stockholders’ Equity

Preferred Stock, $0.001 Par Value. 10,000,000 Shares Authorized; 82,185 Shares Issued and

82,185 Outstanding as of March 31, 2024 and 85,534 Shares Issued and 85,534 Outstanding as of

December 31, 2023.

82

86

Common Stock, $0.001 Par Value. 250,000,000 Shares Authorized; 79,168,539 Shares Issued

and 78,248,389 Shares Outstanding as of March 31, 2024 and 74,888,392 Shares Issued

and 73,968,242 Shares Outstanding as of December 31, 2023.

79,169

74,888

Additional Paid-In Capital

202,677,665

202,040,968

Accumulated Deficit

(96,843,602)

(80,790,927)

Common Stock Held in Treasury, at Cost, 920,150 Shares Held as of March 31, 2024 and

920,150 Shares Held as of December 31, 2023.

(2,033,127)

(2,033,127)

Total Stockholders’ Equity

103,880,187

119,291,888

Total Liabilities & Stockholders’ Equity

$

346,606,776

$

358,144,332

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME AND (LOSS)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Operating Revenues

Retail

$

37,633,252

$

35,820,111

Wholesale

3,898,320

4,058,925

Other

69,421

121,900

Total Revenue

41,600,993

40,000,936

Total Cost of Goods & Services

23,667,319

18,152,163

Gross Profit

17,933,674

21,848,773

Operating Expenses

Selling, General and Administrative Expenses

11,835,818

10,100,934

Professional Services

1,671,881

1,187,364

Salaries

6,880,988

4,695,971

Stock Based Compensation

253,916

214,544

Total Operating Expenses

20,642,603

16,198,813

Income from Operations

(2,708,929)

5,649,960

Other Income (Expense)

Interest Expense, net

(8,307,369)

(7,745,854)

Unrealized Gain (Loss) on Derivative Liabilities

(681,825)

8,501,685

Other Loss

10,500

Loss on Investment

(33,382)

Unrealized Gain on Investment

(347,516)

1,816

Total Other Income (Expense)

(9,359,592)

757,647

Pre-Tax Net Income (Loss)

(12,068,521)

6,407,607

Provision for Income Taxes

3,984,154

4,662,178

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Less: Accumulated Preferred Stock Dividends for the Period

(2,155,259)

(2,029,394)

Net Income (Loss) Attributable to Common Stockholders

$

(18,207,934)

$

(283,965)

Earnings (Loss) per Share Attributable to Common Stockholders

Basic Earnings (Loss) per Share

$

(0.24)

$

(0.01)

Diluted Earnings (Loss) per Share

$

(0.24)

$

(0.06)

Weighted Average Number of Shares Outstanding – Basic

76,006,932

55,835,501

Weighted Average Number of Shares Outstanding – Diluted

76,006,932

101,608,278

Comprehensive Income (Loss)

$

(16,052,675)

$

1,745,429

MEDICINE MAN TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

(Unaudited)

(Unaudited)

Cash Flows from Operating Activities:

Net Income (Loss) for the Period

$

(16,052,675)

$

1,745,429

Adjustments to Reconcile Net Income (Loss) to Cash for Operating Activities

Depreciation & Amortization

5,096,314

6,151,395

Non-Cash Interest Expense

1,031,431

991,184

Non-Cash Lease Expense

2,871,226

2,251,459

Deferred Taxes

1,004,345

(637,225)

Loss on Investment

202,111

Change in Derivative Liabilities

681,825

(8,501,685)

Amortization of Debt Issuance Costs

421,512

421,513

Amortization of Debt Discount

2,303,246

1,999,933

(Gain) Loss on Investments, net

347,516

(1,816)

Stock Based Compensation

640,974

214,544

Changes in Operating Assets & Liabilities (net of Acquired Amounts):

Accounts Receivable

905,127

(118,181)

Inventory

(587,900)

(3,023,251)

Prepaid Expenses & Other Current Assets

411,754

(3,036,801)

Other Assets

(64,350)

360,674

Change in Operating Lease Liabilities

(2,348,703)

(1,531,765)

Accounts Payable & Other Liabilities

(3,566,401)

(3,464,671)

Income Taxes Payable

3,002,257

5,299,403

Net Cash Provided by (Used in) Operating Activities

(3,700,390)

(879,861)

Cash Flows from Investing Activities:

Collection of Notes Receivable

10,631

Purchase of Fixed Assets

(1,532,287)

(2,913,394)

Net Cash Provided by (Used in) Investing Activities

(1,532,287)

(2,902,763)

Cash Flows from Financing Activities:

Payment on Notes Payable

(864,938)

Net Cash Provided by (Used in) Financing Activities

(864,938)

Net (Decrease) in Cash & Cash Equivalents

(6,097,615)

(3,782,624)

Cash & Cash Equivalents at Beginning of Period

19,248,932

38,949,253

Cash & Cash Equivalents at End of Period

$

13,151,317

$

35,166,628

Supplemental Disclosure of Cash Flow Information:

Cash Paid for Interest

$

4,515,205

$

6,540,748

MEDICINE MAN TECHNOLOGIES, INC.
ADJUSTED EBITDA RECONCILIATION (NON-GAAP)
For the Periods Ended March 31, 2024 and 2023
Expressed in U.S. Dollars

For the Three Months Ended

March 31,

2024

2023

Net Income (Loss)

$

(16,052,675)

$

1,745,429

Interest Expense, net

8,307,369

7,745,854

Provision for Income Taxes

3,984,154

4,662,178

Other (Income) Expense, net of Interest Expense

1,052,223

(8,503,501)

Depreciation & Amortization

5,618,834

6,612,814

Earnings Before Interest, Taxes, Depreciation and

Amortization (EBITDA) (non-GAAP)

$

2,909,905

$

12,262,774

Non-Cash Stock Compensation

253,916

214,544

Deal Related Expenses

637,761

1,195,802

Capital Raise Related Expenses

20,760

35,068

Severance

484,561

118,436

Retention Program Expenses

807,500

280,632

Pre-Operating & Dark Carry Expenses

1,053,837

391,917

One-Time Legal Settlements

417,653

Other Non-Recurring Items

754,751

25,707

Adjusted EBITDA (non-GAAP)

$

7,340,644

$

14,524,880

Revenue

41,600,993

40,000,936

Adjusted EBITDA Percent

17.6 %

36.3 %

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-announces-first-quarter-2024-financial-results-302146858.html

Continue Reading
Advertisement

Latest news

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania